Get key insights from TransMedics’ Q3 2025 earnings: strong revenue, margin gains, EU expansion plans, and growth outlook. Discover what drives TMDX forward.
Get key highlights from BridgeBio Pharma’s Q3 2025 earnings: record Attruby sales, positive Phase III results, and strategic outlook for market share growth.
32m
TTM Technologies targets Q4 sales between $730M-$770M while advancing Penang and Syracuse expansions
The company expects SG&A expense to be about 8.9% of net sales, R&D at about 1% of net sales, interest expense of approximately $10.2 million, and an effective tax rate between 11% and 15% for Q4.
Discover Vanda Pharmaceuticals' Q3 2025 results: strong Fanapt growth, updated guidance, and pipeline milestones.
Q3 2025 Earnings Call October 29, 2025 5:00 PM EDTCompany ParticipantsStephen Haymore - Director of Investor RelationsAli El-Haj ...
Q3 2025 Earnings Call October 29, 2025 4:30 PM EDTCompany ParticipantsDaniel Boehle - Executive VP & CFOEdwin Roks ...
Get key insights from Udemy's Q3 2025 earnings call: subscription growth, AI innovations, and financial performance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback